NASDAQ:BIIB - Biogen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$280.4850 +2.81 (+1.01 %)
(As of 05/22/2018 11:12 AM ET)
Previous Close$277.67
Today's Range$278.0101 - $281.04
52-Week Range$244.28 - $370.57
Volume321,493 shs
Average Volume2.00 million shs
Market Capitalization$59.17 billion
P/E Ratio12.86
Dividend YieldN/A

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic


Debt-to-Equity Ratio0.42
Current Ratio3.23
Quick Ratio2.95


Trailing P/E Ratio12.86
Forward P/E Ratio11.74
P/E Growth1.64

Sales & Book Value

Annual Sales$12.27 billion
Price / Sales4.82
Cash Flow$27.0738 per share
Price / Cash10.36
Book Value$59.56 per share
Price / Book4.71


EPS (Most Recent Fiscal Year)$21.81
Net Income$2.54 billion
Net Margins23.54%
Return on Equity37.64%
Return on Assets20.32%


Outstanding Shares211,010,000

Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen (NASDAQ:BIIB) posted its quarterly earnings results on Tuesday, April, 24th. The biotechnology company reported $6.05 earnings per share for the quarter, topping the Zacks' consensus estimate of $5.93 by $0.12. The biotechnology company had revenue of $3.13 billion for the quarter, compared to the consensus estimate of $3.15 billion. Biogen had a net margin of 23.54% and a return on equity of 37.64%. Biogen's revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $5.20 earnings per share. View Biogen's Earnings History.

When is Biogen's next earnings date?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Biogen.

What price target have analysts set for BIIB?

29 brokers have issued twelve-month target prices for Biogen's shares. Their predictions range from $262.15 to $425.00. On average, they expect Biogen's share price to reach $353.9685 in the next twelve months. View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:
  • 1. Mizuho analysts commented, "We also note full year 2017 consensus is already above the company’s guidance on both top and bottom lines (guidance last updated in 2Q17) 1. Spinraza. We believe investors will continue to be focused on the performance of the Spinraza launch and information from management on uptake trends. At the recent JPM conference, BIIB commented that for Spinraza they see a benefit from the new launch period in large territories and then a moderate rate of growth, noting that they see reasonable growth in the US in the coming quarters and that a lot of the growth will come outside the US as new countries receive approvals. This was similar to commentary from management in the 3Q17 call. Consensus has 4Q over 3Q growth of 11% and 51% in the US and Ex-US for Spinraza." (1/18/2018)
  • 2. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
  • 3. Citigroup analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
  • 4. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:
  • Mr. Michel Vounatsos, CEO & Director (Age 56)
  • Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 53)
  • Mr. Gregory F. Covino, VP of Fin. & Chief Accounting Officer (Age 52)
  • Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 61)
  • Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)

Has Biogen been receiving favorable news coverage?

Press coverage about BIIB stock has been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Biogen earned a media sentiment score of 0.16 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.87 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.18%), PRIMECAP MANAGEMENT COMPANY (7.16%), Northern Trust Corp (1.36%), Massachusetts Financial Services Co. MA (0.98%), Summit Trail Advisors LLC (0.71%) and American Century Companies Inc. (0.56%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP, Franklin Resources Inc., Farallon Capital Management LLC, Sei Investments Co., Northern Trust Corp, Swiss National Bank, Woodford Investment Management Ltd and Swedbank. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Brian S Posner, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Which major investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, BlackRock Inc., Rockefeller Capital Management L.P., Old Mutual Global Investors UK Ltd., Massachusetts Financial Services Co. MA, Point72 Asset Management L.P., American Century Companies Inc. and Candriam Luxembourg S.C.A.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $281.0150.

How big of a company is Biogen?

Biogen has a market capitalization of $59.17 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.

MarketBeat Community Rating for Biogen (BIIB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,284 (Vote Outperform)
Underperform Votes:  750 (Vote Underperform)
Total Votes:  2,034
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biogen (NASDAQ:BIIB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
29 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $353.9685, suggesting that the stock has a possible upside of 26.20%. The high price target for BIIB is $425.00 and the low price target for BIIB is $262.15. There are currently 9 hold ratings and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.692.732.66
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
22 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $353.9685$367.2222$369.7857$341.7037
Price Target Upside: 26.20% upside38.71% upside23.52% upside10.56% upside

Biogen (NASDAQ:BIIB) Consensus Price Target History

Price Target History for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018MizuhoSet Price TargetBuy$423.00LowView Rating Details
5/2/2018CitigroupLower Price TargetNeutral ➝ Neutral$360.00 ➝ $290.00LowView Rating Details
4/26/2018Cantor FitzgeraldReiterated RatingNeutralMediumView Rating Details
4/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$365.00 ➝ $369.00LowView Rating Details
4/25/2018Leerink SwannSet Price TargetMarket Perform ➝ Hold$365.00 ➝ $325.00HighView Rating Details
4/25/2018Goldman SachsReiterated RatingConviction-Buy ➝ Buy$388.00 ➝ $262.15HighView Rating Details
4/25/2018Robert W. BairdUpgradeNeutral ➝ OutperformHighView Rating Details
4/24/2018OppenheimerSet Price TargetBuy$375.00HighView Rating Details
4/24/2018Stifel NicolausSet Price TargetBuy$425.00HighView Rating Details
4/24/2018GuggenheimSet Price TargetBuy$385.00HighView Rating Details
4/24/2018Credit Suisse GroupSet Price TargetBuy$384.00HighView Rating Details
4/24/2018SunTrust BanksSet Price TargetBuy$321.00HighView Rating Details
4/24/2018Piper Jaffray CompaniesLower Price TargetOverweightHighView Rating Details
4/24/2018CowenReiterated RatingBuy$408.00HighView Rating Details
4/24/2018Jefferies GroupReiterated RatingHold$375.00 ➝ $300.00HighView Rating Details
4/10/2018Sanford C. BernsteinSet Price TargetBuy$318.00MediumView Rating Details
4/9/2018Canaccord GenuitySet Price TargetHold$350.00MediumView Rating Details
4/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$395.00 ➝ $295.00HighView Rating Details
3/2/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$403.00 ➝ $393.00LowView Rating Details
2/16/2018ArgusDowngradeBuy ➝ HoldMediumView Rating Details
2/15/2018William BlairReiterated RatingBuyLowView Rating Details
2/8/2018JPMorgan ChaseReiterated RatingBuyHighView Rating Details
1/31/2018UBSUpgradeNeutral ➝ Buy$352.59 ➝ $410.00LowView Rating Details
1/26/2018Deutsche BankReiterated RatingBuy$373.00LowView Rating Details
1/26/2018Royal Bank of CanadaBoost Price TargetSector Perform$347.00HighView Rating Details
1/26/2018HC WainwrightReiterated RatingBuy ➝ Buy$340.00 ➝ $363.00HighView Rating Details
12/30/2017NomuraBoost Price TargetBuy$355.00 ➝ $420.00N/AView Rating Details
10/18/2017Bank of AmericaBoost Price TargetBuy$358.00 ➝ $365.00N/AView Rating Details
9/21/2017Raymond JamesDowngradeStrong-Buy ➝ Market Perform$244.28 ➝ $319.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy ➝ Buy$223.03 ➝ $345.00N/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy ➝ HoldN/AView Rating Details
6/8/2016Wells FargoReiterated RatingBuyN/AView Rating Details
(Data available from 5/22/2016 forward)


Biogen (NASDAQ:BIIB) Earnings History and Estimates Chart

Earnings by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) Earnings Estimates

2018 EPS Consensus Estimate: $23.78
2019 EPS Consensus Estimate: $26.07
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20186$5.54$6.04$5.93
Q2 20186$4.02$6.35$5.26
Q3 20186$6.14$6.42$6.29
Q4 20186$5.99$6.63$6.31
Q1 20193$6.06$6.30$6.21
Q2 20193$6.51$6.71$6.58
Q3 20192$6.49$6.92$6.71
Q4 20192$6.20$6.93$6.57

Biogen (NASDAQ BIIB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/23/2018$5.34N/AView Earnings Details
4/24/2018Q1 2018$5.93$6.05$3.1518 billion$3.1310 billionViewN/AView Earnings Details
1/25/2018Q4 2017$5.44$5.26$3.0841 billion$3.3070 billionViewListenView Earnings Details
10/24/2017Q3 2017$5.70$6.31$3.0467 billion$3.0780 billionViewN/AView Earnings Details
7/25/2017Q2 2017$4.36$5.04$2.8133 billion$3.0780 billionViewN/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.7287 billion$2.8110 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
10/26/2010Q3 2010$1.20$1.33ViewN/AView Earnings Details
7/20/2010Q2 2010$1.08$1.28ViewN/AView Earnings Details
4/20/2010Q1 2010$1.12$1.05ViewN/AView Earnings Details
2/9/2010Q4 2009$1.05$1.17ViewN/AView Earnings Details
10/20/2009Q3 2009$1.02$1.09ViewN/AView Earnings Details
7/16/2009Q2 2009$0.89$0.73ViewN/AView Earnings Details
4/16/2009Q1 2009$1.00$1.05ViewN/AView Earnings Details
2/6/2009Q4 2008$0.88$0.91ViewN/AView Earnings Details
10/21/2008Q3 2008$0.89$0.95ViewN/AView Earnings Details
7/22/2008Q2 2008$0.83$0.91ViewN/AView Earnings Details
4/23/2008Q1 2008$0.78$0.82ViewN/AView Earnings Details
2/6/2008Q4 2007$0.79$0.89ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Biogen (NASDAQ:BIIB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.29%
Institutional Ownership Percentage: 87.31%
Insider Trading History for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ BIIB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/25/2018Alexander J DennerDirectorBuy48,000$269.91$12,955,680.0010,029View SEC Filing  
2/27/2018Alfred SandrockEVPSell259$290.83$75,324.976,553View SEC Filing  
2/20/2018Alfred SandrockEVPSell743$292.00$216,956.006,553View SEC Filing  
2/15/2018Alfred SandrockEVPSell1,294$298.85$386,711.907,296View SEC Filing  
1/9/2018Robert W PangiaDirectorSell5,832$329.65$1,922,518.8023,539View SEC Filing  
12/29/2017Michel VounatsosCEOBuy780$320.55$250,029.00View SEC Filing  
12/29/2017Michel VounatsosCEOBuy780$320.55$250,029.004,879View SEC Filing  
11/29/2017Alexander J DennerDirectorBuy30,000$317.36$9,520,800.0010,029View SEC Filing  
7/25/2017Susan H AlexanderEVPSell4,974$290.01$1,442,509.7422,258View SEC Filing  
7/19/2017Susan H AlexanderEVPSell7,758$285.00$2,211,030.0027,232View SEC Filing  
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.046,330View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.0010,813View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.487,060View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.0520,705View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.5022,078View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.287,579View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.007,172View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.0019,663View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.0054,779View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.002,402View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.0054,936View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.7056,265View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.0059,633View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.3859,790View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.001,848View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.0060,277View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.2160,434View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.1960,921View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.608,127View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.707,990View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.527,990View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.9259,848View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.087,740View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.007,740View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.007,890View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.155,749View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.8824,019View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.006,970View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.6626,142View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.0014,003View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.006,435View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.0014,468View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.457,976View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.438,191View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.243,511View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.1854,389View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.1621,407View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.809,412View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.3513,667View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.3652,961View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.8010,440View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.003,325View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.0018,509View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.5014,003View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.003,325View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.008,710View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.007,087View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.984,885View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.107,087View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.008,710View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.6043,522View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.804,571View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)


Biogen (NASDAQ BIIB) News Headlines

Vivus Stock Rose 60% Last WeekVivus Stock Rose 60% Last Week - May 22 at 8:17 AM
BlueBird Bio Stock Jumps over 6% on May 17BlueBird Bio Stock Jumps over 6% on May 17 - May 18 at 8:31 AM
Amgen Stock Rises over 2% on Drug ApprovalsAmgen Stock Rises over 2% on Drug Approvals - May 18 at 8:31 AM
No FDA Seal of Approval for These Big BiotechsNo FDA Seal of Approval for These Big Biotechs - May 17 at 6:49 PM
Biogen, Shire called out by FDA for ‘gaming’ generic access ruleBiogen, Shire called out by FDA for ‘gaming’ generic access rule - May 17 at 6:49 PM
Biogen (BIIB) Expected to Post Quarterly Sales of $3.24 BillionBiogen (BIIB) Expected to Post Quarterly Sales of $3.24 Billion - May 15 at 4:40 AM
Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer?Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer? - May 14 at 5:22 PM
$5.29 EPS Expected for Biogen (BIIB) This Quarter$5.29 EPS Expected for Biogen (BIIB) This Quarter - May 13 at 3:19 AM
Biogen (BIIB) Upgraded by ValuEngine to "Hold"Biogen (BIIB) Upgraded by ValuEngine to "Hold" - May 12 at 5:01 PM
Positive prospects for biotech giants Biogen, Celgene, Gilead and RegeneronPositive prospects for biotech giants Biogen, Celgene, Gilead and Regeneron - May 11 at 8:21 AM
Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospectsCramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects - May 11 at 8:21 AM
Cramer Remix: The one thing that’s keeping the market fro...Cramer Remix: The one thing that’s keeping the market fro... - May 11 at 8:21 AM
Biogen (BIIB) Receives Average Recommendation of "Buy" from AnalystsBiogen (BIIB) Receives Average Recommendation of "Buy" from Analysts - May 10 at 3:00 PM
3 Stocks That Turned $10000 Into $1 Million3 Stocks That Turned $10000 Into $1 Million - May 9 at 5:37 PM
Our Free Research Report on Biogen and More Biotech StocksOur Free Research Report on Biogen and More Biotech Stocks - May 9 at 8:16 AM
Biogen (BIIB) Downgraded to Sell at ValuEngineBiogen (BIIB) Downgraded to Sell at ValuEngine - May 3 at 11:47 PM
Mizuho Analysts Give Biogen (BIIB) a $423.00 Price TargetMizuho Analysts Give Biogen (BIIB) a $423.00 Price Target - May 3 at 1:31 PM
Bristol-Myers Squibb and Biogen Are the Pharmas Most Trusted by Doctors, Study FindsBristol-Myers Squibb and Biogen Are the Pharmas Most Trusted by Doctors, Study Finds - May 2 at 5:39 PM
Biogen Buy Signal: Alzheimers Royalties OptionBiogen Buy Signal: Alzheimer's Royalties Option - May 2 at 5:39 PM
Biogen Director Denner Buys $13 Million in StockBiogen Director Denner Buys $13 Million in Stock - May 2 at 5:38 PM
Citigroup Trims Biogen (BIIB) Target Price to $290.00Citigroup Trims Biogen (BIIB) Target Price to $290.00 - May 2 at 11:11 AM
Biogen (BIIB) Raised to "B-" at TheStreetBiogen (BIIB) Raised to "B-" at TheStreet - May 2 at 10:25 AM
BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimers Disease Investigational Treatment ...BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment ... - May 1 at 5:20 PM
Biogen adding 150 jobs in RTPBiogen adding 150 jobs in RTP - May 1 at 5:20 PM
Better Buy: Biogen Inc. vs. Gilead Sciences Inc.Better Buy: Biogen Inc. vs. Gilead Sciences Inc. - May 1 at 8:22 AM
Biogen will pay $50 million to reduce royalties on Alzheimers disease drugBiogen will pay $50 million to reduce royalties on Alzheimer's disease drug - May 1 at 8:22 AM
Insider Buys Of The Week: Apollo Global, Biogen And MoreInsider Buys Of The Week: Apollo Global, Biogen And More - April 29 at 10:42 AM
BRIEF-Biogen CEO Michel Vounatsos Total Compensation For 2017 Was $13.7 MillionBRIEF-Biogen CEO Michel Vounatsos' Total Compensation For 2017 Was $13.7 Million - April 27 at 5:17 PM
Heres Why 275% in Biogen Inc Stock Looks RealisticHere's Why 275% in Biogen Inc Stock Looks Realistic - April 27 at 5:17 PM
Here’s Why 275% in Biogen Inc Stock Looks RealisticHere’s Why 275% in Biogen Inc Stock Looks Realistic - April 27 at 2:09 PM
Biogen (BIIB) Lifted to Hold at BidaskClubBiogen (BIIB) Lifted to Hold at BidaskClub - April 27 at 12:13 PM
Biogen (BIIB) Director Alexander J. Denner Purchases 48,000 SharesBiogen (BIIB) Director Alexander J. Denner Purchases 48,000 Shares - April 27 at 10:24 AM
Q3 2018 EPS Estimates for Biogen (BIIB) Boosted by SunTrust BanksQ3 2018 EPS Estimates for Biogen (BIIB) Boosted by SunTrust Banks - April 27 at 8:55 AM
Leerink Swann Weighs in on Biogens Q3 2018 Earnings (BIIB)Leerink Swann Weighs in on Biogen's Q3 2018 Earnings (BIIB) - April 27 at 8:55 AM
Biogen (BIIB) to Post Q2 2018 Earnings of $5.22 Per Share, Jefferies Group ForecastsBiogen (BIIB) to Post Q2 2018 Earnings of $5.22 Per Share, Jefferies Group Forecasts - April 27 at 8:04 AM
Oppenheimer Brokers Cut Earnings Estimates for Biogen (BIIB)Oppenheimer Brokers Cut Earnings Estimates for Biogen (BIIB) - April 27 at 8:04 AM
$3.23 Billion in Sales Expected for Biogen (BIIB) This Quarter$3.23 Billion in Sales Expected for Biogen (BIIB) This Quarter - April 27 at 2:38 AM
Brian Skorney on Biogen EarningsBrian Skorney on Biogen Earnings - April 26 at 5:19 PM
Analyst Recommendations for Biogen in AprilAnalyst Recommendations for Biogen in April - April 26 at 5:19 PM
FY2020 EPS Estimates for Biogen (BIIB) Lowered by AnalystFY2020 EPS Estimates for Biogen (BIIB) Lowered by Analyst - April 26 at 11:28 AM
FY2020 EPS Estimates for Biogen Boosted by William Blair (BIIB)FY2020 EPS Estimates for Biogen Boosted by William Blair (BIIB) - April 26 at 11:28 AM
Biogens (BIIB) Neutral Rating Reiterated at Cantor FitzgeraldBiogen's (BIIB) Neutral Rating Reiterated at Cantor Fitzgerald - April 26 at 10:32 AM
Jefferies Group Weighs in on Biogens Q3 2018 Earnings (BIIB)Jefferies Group Weighs in on Biogen's Q3 2018 Earnings (BIIB) - April 26 at 9:50 AM
Piper Jaffray Analysts Reduce Earnings Estimates for Biogen (BIIB)Piper Jaffray Analysts Reduce Earnings Estimates for Biogen (BIIB) - April 26 at 9:24 AM
3 Things In Biotech, April 25: Biogen Advances, Prothena Crashes, Lilly Survives3 Things In Biotech, April 25: Biogen Advances, Prothena Crashes, Lilly Survives - April 26 at 8:14 AM
Blog Exposure - Galapagos Commenced First Clinical Trial FALCON with Investigational Triple Combination Therapy in Cystic Fibrosis PatientsBlog Exposure - Galapagos Commenced First Clinical Trial FALCON with Investigational Triple Combination Therapy in Cystic Fibrosis Patients - April 26 at 8:14 AM
Biogen’s Fampyra and Interferons in 1Q18Biogen’s Fampyra and Interferons in 1Q18 - April 26 at 8:14 AM
Biotech Bounceback: Amgen, Biogen Gain BelieversBiotech Bounceback: Amgen, Biogen Gain Believers - April 25 at 5:30 PM
Biogen Q1 2018: Too Cheap To IgnoreBiogen Q1 2018: Too Cheap To Ignore - April 25 at 5:30 PM
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on SalesBiotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales - April 25 at 5:30 PM

SEC Filings

Biogen (NASDAQ:BIIB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement


Biogen (NASDAQ BIIB) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.